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Abstract CRAC channel regulator 2 A (CRACR2A) is a large Rab GTPase that is expressed abun-
dantly in T cells and acts as a signal transmitter between T cell receptor stimulation and activation of 
the Ca2+- NFAT and JNK- AP1 pathways. CRACR2A has been linked to human diseases in numerous 
genome- wide association studies, however, to date no patient with damaging variants in CRACR2A 
has been identified. In this study, we describe a patient harboring biallelic variants in CRACR2A 
[paternal allele c.834 gaG> gaT (p.E278D) and maternal alelle c.430 Aga > Gga (p.R144G) c.898 
Gag> Tag (p.E300*)], the gene encoding CRACR2A. The 33- year- old patient of East- Asian origin 
exhibited late onset combined immunodeficiency characterised by recurrent chest infections, panhy-
pogammaglobulinemia and CD4+ T cell lymphopenia. In vitro exposure of patient B cells to a T- de-
pendent stimulus resulted in normal generation of antibody- secreting cells, however the patient’s T 
cells showed pronounced reduction in CRACR2A protein levels and reduced proximal TCR signaling, 
including dampened SOCE and reduced JNK phosphorylation, that contributed to a defect in 
proliferation and cytokine production. Expression of individual allelic mutants in CRACR2A- deleted 
T cells showed that the CRACR2AE278D mutant did not affect JNK phosphorylation, but impaired 
SOCE which resulted in reduced cytokine production. The truncated double mutant CRACR2AR144G/
E300* showed a pronounced defect in JNK phosphorylation as well as SOCE and strong impairment in 
cytokine production. Thus, we have identified variants in CRACR2A that led to late- stage combined 
immunodeficiency characterized by loss of function in T cells.
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The study is the first report and characterization of impaired immune function in an individual with 
biallelic mutations in the CRACR2A gene. The mechanistic insights from this study, are an important 
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advance in the understanding of CRAC channels and the regulation of calcium dynamics in the T- cell 
lineage. The work will be of interest to cell biologists, immunologists and those with interests in 
intracellular signaling.
Introduction
T cell activation following antigen recognition involves several signaling events. Amongst others, these 
include Ca2+ influx and activation of the c- Jun N- terminal kinase (JNK) and p38 mitogen- activated 
protein kinase (MAPK) pathways. The Ca2+ influx is initiated shorty after T cell receptor (TCR) engage-
ment, and involves activation of phospholipase Cγ and production of inositol- 1,4,5- trisphosphate (IP3). 
The latter binds to IP3 receptors in the endoplasmic reticulum (ER) membrane, leading to receptor- 
mediated release of Ca2+ from the ER. The Ca2+ release is detected by stromal interaction mole-
cules (STIM) - STIM1 and STIM2, which are EF- hand- containing proteins, located in the ER membrane 
(Roos et al., 2005; Liou et al., 2005). Depletion of the ER Ca2+ stores leads to Ca2+- loss from the 
STIM1 EF- hand causing it to multimerize and translocate to the ER in close proximity to the plasma 
membrane (PM). Subsequently, STIM1 binds to PM- resident ORAI1, which is the pore subunit of the 
Ca2+ release–activated Ca2+ (CRAC) channel, resulting in the opening of the channel and Ca2+ influx 
(Feske et al., 2006; Zhang et al., 2006; Vig et al., 2006). This process is otherwise known as store- 
operated Ca2+ entry (SOCE) since it depends on the filling state of the ER Ca2+ stores. The importance 
of Ca2+ influx for lymphocyte proliferation, differentiation and function, and the role that STIM1 and 
ORAI1 play in these processes, is illustrated by rare primary immunodeficiency syndromes caused 
by autosomal recessive (AR) loss of function (LOF) or null mutations in ORAI1 and STIM1 genes. The 
affected patients tend to present from early age with varying degrees of immune defects, ranging 
from severe combined immunodeficiency (SCID), to milder forms, where the immune impairment is 
functionally evident, but not associated with any apparent immunodeficiency (Feske et al., 2006; 
Chou et al., 2015; Fuchs et al., 2012; McCarl et al., 2009; Picard et al., 2009; Parry et al., 2016; 
Rice et  al., 2019; Byun et  al., 2010; Schaballie et  al., 2015). Patients with SCID- like phenotype 
present with severe viral, bacterial, and fungal infections. In many cases there is associated immune 
dysregulation manifesting as lymphoproliferation or autoimmunity (Picard et al., 2009). In most cases 
it is the function rather than numbers of lymphocytes that is affected. Lastly, non- immunological mani-
festations are common, such as congenital muscular hypotonia, defects in dental enamel develop-
ment, and anhidrosis, due to critical role of SOCE for these physiological functions (Parry et al., 2016; 
Rice et al., 2019; Wang et al., 2014; Lian et al., 2018).
CRAC Channel Regulator 2 A (CRACR2A) was identified as a protein that binds ORAI1/STIM1 and 
stabilizes their interaction to mediate SOCE in T cells (Srikanth et al., 2010a). Two isoforms of the 
protein are expressed in T cells, a short cytoplasmic isoform CRACR2A- c, that was originally shown 
to bind ORAI1/STIM1 and stabilize their interaction, and a longer isoform CRACR2A- a (hereafter 
referred to as CRACR2A), that is a Rab GTPase. CRACR2A (also called EFCAB4B and Rab46) is abun-
dantly expressed in T cells and belongs to a family of large Rab GTPases that also includes Rab44 and 
Rab45. It is a protein with multiple functional domains including an N- terminal Ca2+- binding EF- hand 
(also present in the shorter CRACR2A- c isoform), a protein- interacting coiled coil domain and proline- 
rich domain, and a C- terminal Rab GTPase domain. This long isoform is prenylated at its C terminus 
and predominantly localizes to vesicles and Golgi in T cells. Both the isoforms interact with ORAI1 and 
STIM1 and are involved in regulation of SOCE (Srikanth et al., 2010a). In addition to regulation of 
SOCE, CRACR2A has also been shown to interact with Vav1 and regulate JNK phosphorylation. The 
GTPase domain of CRACR2A and prenylation have been shown to be necessary for its role in JNK 
activation (Srikanth et al., 2016).
The human CRACR2A (formerly EFCAB4B) gene is located on chromosome 12. Associations 
between polymorphisms in CRACR2A and human diseases have been identified from numerous 
genome- wide association studies (GWAS) of Parkinson disease, nonalcoholic fatty liver disease, atrial 
fibrillation, and chronic infection of HIV type (Fung et al., 2006; Chalasani and Björnsson, 2010; 
Tan et al., 2013; Iglesias- Ussel et al., 2013; Edelman et al., 2015). However, until now, CRACR2A 
has not directly been linked with a primary immunodeficiency (PID) in humans. Here, we describe a 
single case of late onset combined immunodeficiency due to biallelic variants in CRACR2A which 
encodes CRACR2A. One of the alleles encodes a truncated protein containing another point mutation 
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in the EF- hand domain (CRACR2A p.[R144G/E300*], hereafter referred to as double mutant DM), 
whereas the other allele encodes a point mutant (CRACR2A p.E278D), with the mutation residing in 
the protein- interacting coiled coil region of the protein. Exogenous expression of individual allelic 
mutations in T cells shows that the DM impairs both SOCE as well as JNK phosphorylation, whereas 
p.E278D selectively impairs SOCE.
Results
Case presentation and immunological work up
We evaluated a 33- year- old male of East- Asian origin. He originally presented to gastroenterology 
services at the age of 19 years with chronic diarrhea. Following initial assessment, which included 
normal colonoscopy and negative coeliac screen, he was found to have severe panhypogammaglob-
ulinaemia and was referred to clinical immunology for further investigations. On further questioning 
the patient reported a 5- year long history of recurrent lower respiratory tract infections requiring 
treatment with antibiotics. He also reported having a left lower lobe pneumonia at 15 years of age. 
He had no other significant infection history and reported being generally well during his childhood. 
His only other past medical history of note was appendicectomy at the age of 10 years. He had no 
Figure 1. Clinical and immunological features of index patient. (A) A computerized tomography scan of the chest showing area of cylindrical 
bronchiectasis at the basal segment of the left lower lobe. (B) TCR repertoire as assessed by T receptor spectraphenotyping. Data are representative of 
one independent assay. (C) Phytohaemagglutinin (PHA) and (D) anti- CD3 T cell proliferation. CPM (counts per minute). Data are representative of three 
independent assays.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. T helper (TH) TH1, TH2, and TH17 peripheral blood phenotyping.
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history of developmental difficulties, dental, skin or any musculoskeletal abnormalities. He was an 
only child from non- consanguineous parents with no family history of PID. Shortly after presenting to 
immunology, he developed a left hip and iliac fossa pain and was found to have multiloculated left 
psoas abscess which required a computerized tomography (CT) guided drainage and prolonged anti-
biotic treatment. This infective episode was complicated by pulmonary embolism (incidental finding 
on a repeat CT scan) for which he was anticoagulated for a period of 6 months. He had no subsequent 
history of thromboembolic events. A detailed CT scan of his chest showed cylindrical bronchiectasis 
of the left lower lobe, lingua and R middle lobe. This appearance remains unchanged as shown on a 
repeat scan 11 years later in 2016 (Figure 1A).
The initial immunological investigations showed profound panhypogammaglobulinaemia with 
drastically reduced IgG and undetectable IgA and IgM levels (Table 1). The basic lymphocyte profiling 
showed mild CD4+ T cell lymphopenia with adequate numbers of B and NK cells. Subsequent detailed 
phenotyping revealed reduced proportion of naïve T cells and seemingly adequate percentages of 
central and effector memory T cells. The proportion of TH1/TH2 and TH17 T cells was comparable 
to healthy controls (Figure 1—figure supplement 1) and TCR phenotyping showed a normal TCR 
repertoire (Figure 1B). The patient also had reduced proportion of class switched memory B cells 
(Table 1). Functional testing showed reduced T cell proliferation to both PHA and anti- CD3 stimula-
tion (Figure 1C and D). Over the next 15 years, there was evidence of progressive CD4+ T cell and B 
cell lymphopenia. Interestingly, biopsy of his large bowel, which was performed in 2011 for investiga-
tion of intermittent diarrhoea, showed mild non- specific inflammatory changes, but also absence of 
the plasma cells.
Following the initial assessment, the patent was given a provisional diagnosis of common vari-
able immunodeficiency (CVID) and treated with regular intravenous immunoglobulin (IVIG) replace-
ment therapy. His clinical progress since the diagnosis has been uncomplicated. His chronic diarrhoea 
resolved following commencement of IVIG and the ongoing treatment with IVIG has resulted in excel-
lent control of respiratory infections.
A rare biallelic variants in CRACR2A identified by exome sequencing
The patient was consented for genetic testing and whole- exome sequencing was performed. Full 
details regarding candidate variant selection are provided in methods. Three potentially damaging 
rare variants were identified in CRACR2A GRCh37 12:3715799–3873985 ENSG00000130038 
ENST00000440314 (c.430A > G; p.R144G, c.898G > T; p.E300*, exons 6/20 and 10/20), which were 
maternal and c.834G > T; p.E278D in exon 9/20 on the other allele. Only c.834G > T is present in the 
gnomAD database, though it is considered rare (heterozygous only; 0.00095 in East Asian). All three 
amino acids are highly conserved in other species.
The variants were confirmed in the genomic DNA by Sanger sequencing the proband and the 
mother and maternal grandmother and the father, with the pedigree shown in Figure 2A. Compound 
heterozygous segregation of these variants was confirmed by subcloning of the proband cDNA to 
isolate the individual alleles. Sanger sequencing confirmed the c.834 G > T variant on a separate allele 
to the other variants (Figure 2B). The protein domains affected by the mutations are schematically 
depicted in Figure 2C.
To check whether the mutant proteins are expressed, we performed immunoblot analyses using T 
cells from patient and healthy control. Peripheral blood mononuclear cells (PBMCs) harvested from the 
patient and healthy control were stimulated with plate- coated anti- CD3 and anti- CD28 antibodies for 
48 hr, following which they were further expanded for a further 4 days and then harvested for making 
cellular lysates. Western blot analysis using anti- CRACR2A antibodies detected reduced amounts of only 
the higher molecular weight band (corresponding to the long isoform) in patient samples (Figure 2D, 
left panel). The antibody was targeting the N- terminal 160 amino acids of CRACR2A, and hence it 
should detect the ~30 KDa truncated form of the p.E300* variant, if expressed. However, we could not 
detect presence of any band at ~30 KDa, suggesting possibly degradation of the truncated form. To 
check for CRACR2A transcript levels, we used primers that were common to both isoforms, however, 
we detected pronounced reduction in CRACR2A transcript levels from patient samples (Figure 2D, 
right panel). Further, in healthy control samples, expression of CRACR2A transcripts increased after 
stimulation with PMA and ionomycin by more than two- fold, but it was not upregulated in patient T 
cells. These data suggest possible nonsense- mediated mRNA decay for CRACR2A transcripts.
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Patient B cells exhibit intact plasma cell generation
Since the patient exhibited profound panhypogammaglobulinaemia and a relative decline in memory 
B and plasma cell populations, we next checked whether patient B cells were functional. To test if the 
panhypogammaglobulinaemia is due to an intrinsic B cell defect, we set up an in vitro culture system 
with a T cell- dependent (TD) stimulus that enables the generation of mature plasma cells from primary 
B cells (Figure 3A; Cocco et al., 2012). The capacity of the patient’s B cells to differentiate into plasma 
cells was comparable to healthy controls, as judged by the acquisition of CD38 and CD138 surface 
expression, which is associated with the transition to an antibody- secreting state (Figure 3B). Further-
more, assessment of immunoglobin levels in cell culture showed adequate production of IgM and IgG 
(Figure 3C), suggesting that the failure of antibody production in this case might be secondary to 
inadequate in vivo T cell help.
Figure 2. A rare biallelic mutation in CRACR2A segregates with the disease. (A) Pedigree showing the index case and p.[R144G/E300*] and p.E278D 
CRACR2A variant carriers. The circles and squares represent female and male members, respectively. Black shading shows affected individuals, 
either heterozygous (partial black) or homozygous (completely black). (B) Sanger sequencing data of the proband showing the indicated mutations. 
(C) Schematic of human CRACR2A showing the location of compound heterozygous mutations from the patient’s alleles. The maternal allele comprised 
of an p.R144G variant that was located in the EF- hand motif and an p.E300* truncation variant within the leucine- rich region (LR). The paternal allele 
contained the p.E278D variant that was located in the coiled- coil domain 2 (CC1 and CC2). CRACR2A also contains a proline- rich domain (PRD) and a 
C- terminal Rab GTPase domain. (D) Detection of CRACR2A in human PBMCs harvested from healthy control and patient by immunoblotting (left) and 
real- time quantitative RT- PCR (right). For qRT- PCR, cells were left unstimulated or re- stimulated with PMA plus ionomycin for 5 hr. β-actin was used as a 
loading control for immunoblotting. Immunoblot is representative of two independent experiments and mRNA analysis shows representative triplicate 
from two independent experiments. * p < 0.05.
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Patient T cells show reduced cytokine expression due to decreased 
Ca2+ influx and JNK activation
Since the patient B cells produced antibodies in vitro, in response to TD antigen, we surmised that 
panhypogammaglobulinaemia is likely due to defect in T cell function. Previously we showed that 
Cracr2a KO mice had a defect in effector of T cell functions (Woo et al., 2018). Hence, we further 
analyzed phenotypes of patient T cells, including TCR- proximal signaling events and cytokine produc-
tion. Patient CD4+ cells produced less IFN-γ than the ones isolated from a representative healthy 
donor (Figure 4A). We extended our findings using cells from multiple healthy donors and different 
batches of the patient cells by checking expression of IFN-γ, IL- 2, and TNF using quantitative RT- PCR 
(Figure 4B) and ELISA (Figure 4C). Expression of all these cytokines was impaired in patient T cells 
compared to control T cells derived from multiple different healthy donors. Since CRACR2A is known 
to interact with ORAI1 and STIM1, to regulate SOCE and JNK phosphorylation (Srikanth et  al., 
2010a; Srikanth et  al., 2016), we measured SOCE after anti- CD3 cross- linking as well as passive 
depletion of the ER Ca2+ stores using thapsigargin, a SERCA blocker. In both these analyses, patient 
cells showed significant reduction in SOCE, when compared to those from representative healthy 
controls (Figure 4D and E). Further, patient T cells also showed a profound defect in JNK phosphory-
lation upon TCR cross- linking (Figure 4F). To confirm that reduced SOCE in patient cells is not due to 
Figure 3. Patient B cell responses to T cell- dependent (TD) stimulation. (A) Schematic representation of the 
culture conditions used to assess plasma cell differentiation in vitro. PBs – Plasmablasts, PCs – Plasma cells 
(B) Representative flow plots showing CD38 and CD138 expression profile following TD stimulation with F(ab’)
two anti- IgG/M and CD40L. Percentages are indicated within individual quadrants. Data are representative of 2 
independent assays. (C) Secreted levels of IgM (left) and IgG (right) from the cells in (B) at indicated time points. 
HC1- 5 (Healthy control) represents data from five independent healthy donor cells.
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altered expression of CRAC channel subunits, we checked expression of ORAI1 and STIM1 in lysates 
of T cells from healthy controls and patient. Expression of ORAI1 and STIM1 were similar between 
control and patient T cells as judged by immunoblotting as well as real- time quantitative RT- PCR 
measurements (Figure 4—figure supplement 1). Together, these results show the conserved role of 
CRACR2A in effector T cell responses by regulating the Ca2+ and JNK pathways in human effector T 
cells, consistent with the previous finding in murine T cells (Woo et al., 2018).
Figure 4. Patient T cell responses to T cell receptor stimulation. (A) Representative flow plots showing expression of IFN-γ in human PBMCs from 
a healthy donor and the patient. PBMCs were stimulated with anti- CD3 and anti- CD28 antibodies for 48 hr and cultured for further 4 days in the 
presence of IL- 2 before re- stimulation with PMA plus ionomycin for 5 hr for cytokine analysis. Cells were gated for CD4+ T cells. (B) Quantitative mRNA 
expression analysis (± s.d.m.) of indicated cytokines from human PBMCs (cultured as mentioned above) with or without stimulation with PMA plus 
ionomycin for 5 hr. (C) Levels of IL- 2 and TNF in human PBMCs from culture supernatants of cells stimulated as described above (B) were determined 
by ELISA. (D) Representative traces showing averaged (± SEM) SOCE responses from healthy control and patient PBMCs (cultured as indicated in A), 
after transient stimulation with anti- CD3 antibody cross- linking, or ionomycin (0.5 µM) in the presence of external solution containing 2 mM Ca2+ (left) 
as indicated. Bar graphs show baseline subtracted ratio values for anti- CD3 antibody cross- linking or ionomycin (average± SEM) from six independent 
experiments (right). (E) Representative traces showing averaged (± SEM) SOCE responses from healthy control and patient PBMCs (cultured as indicated 
in A), after store- depletion with thapsigargin (1 µM) stimulation in Ca2+- free Ringer’s solution. SOCE was measured by addition of 2 mM Ca2+- containing 
Ringer’s solution as indicated (left). Bar graph shows baseline subtracted ratio values at the peak of SOCE (average± SEM) from four independent 
experiments (right). (F) Phosphorylated JNK levels in CD4+ T cells from healthy control and patient PBMCs (cultured as indicated in A), stimulated with 
anti- CD3 antibody for indicated times. Bar graphs show average± SEM from three independent experiments. ** p < 0.005, *** p < 0.0001.
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. Expression of ORAI1 and STIM1 in PBMCs from healthy control and patient.
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Mutations of E278D and R144G/E300* lead to reduced cytokine 
production in T cells
To gain insight into the phenotypes of mutants derived from individual CRACR2A alleles in the 
patient, we first cloned the mutant cDNA in a lentiviral vector. When overexpressed in HEK293 cells, 
E278D and R144G/E300* mutants migrated at the expected molecular weights of ~90 and ~ 30 kDa, 
respectively (Figure 5—figure supplement 1A). To check their expression without interference from 
endogenous CRACR2A proteins, we generated CRACR2A KO Jurkat T cells using the lentivirus- based 
CRISPR/Cas9 system and found that sgRNA#1 and #2 had a great deletion efficiency (Figure 5—
figure supplement 1B). When we stably expressed E278D and R144G/E300* mutants in CRACR2A 
KO Jurkat cells (sgRNA#2), these mutants migrated at their expected molecular weights, similarly 
Figure 5. Cytokine expression profiles in T cells expressing individual allelic mutations in CRACR2A. (A) Representative flow plots showing expression 
of IL- 2 in control or CRACR2A KO Jurkat T cells stably expressing FLAG- tagged WT CRACR2A, CRACR2AE278D (E278D), or CRACR2AR144G/E300* (DM) after 
stimulation with PMA plus ionomycin for 16 hr (left). Bar graph shows means ± s.e.m. of pooled technical replicates from two independent experiments 
(right). (B) Representative flow plots showing expression of IFN-γ in primary human CD4+ T cells transduced with lentiviruses encoding CRACR2A- 
targeting sgRNA and those encoding cDNAs of WT or indicated mutants of CRACR2A after stimulation with anti- CD3 and anti- CD28 antibodies for 5 hr 
(left). Bar graph (right) shows means ± s.e.m. of pooled technical replicates from three independent experiments. (C) Representative flow plots showing 
expression of IFN-γ in primary human CD4+ T cells purified from healthy donors and transduced with lentiviruses encoding cDNAs for WT or indicated 
mutant of CRACR2A after stimulation with anti- CD3 and anti- CD28 antibodies for 5 hr (left). Bar graph (right) shows means ± s.e.m. of pooled technical 
replicates from three independent experiments. * p < 0.05, *** p < 0.0001.
The online version of this article includes the following figure supplement(s) for figure 5:
Figure supplement 1. Expression profile of individual allelic mutants of CRACR2A in different cell types.
 Research article Immunology and Inflammation
Wu, Rice, et al. eLife 2021;0:e72559. DOI: https:// doi. org/ 10. 7554/ eLife. 72559  10 of 25
with HEK293 cells. Notably, even after repeated transduction the expression of R144G/E300* mutant 
protein was much lower than WT or E278D CRACR2A, suggesting that the transcripts of this double 
mutant may be unstable, similar to our observation with patient cells (Figure 2D).
Similar to patient T cells, CRACR2A KO Jurkat T cells showed reduced IL- 2 production (Figure 5A). 
Stable expression of WT CRACR2A in these cells substantially rescued the IL- 2 production defect, 
validating that the decrease was caused due to loss of CRACR2A. However, expression of E278D or 
R144G/E300* mutants showed very marginal rescue of IL- 2 expression in CRACR2A KO Jurkat T cells 
under the same condition. We also validated these results with primary human CD4+ cells. We found 
that transduction with lentiviral vectors encoding sgRNA to delete CRACR2A resulted in reduced 
IFN-γ production in primary cells, which was completely rescued by expression of WT CRACR2A 
(Figure 5B). However, both E278D and R144G/E300* mutants did not rescue cytokine production in 
the KO primary T cells, similar to our observations with Jurkat T cells. Exogenous expression of WT 
CRACR2A in primary T cells from healthy donors (in the presence of WT CRACR2A) slightly enhanced 
IFN-γ production while the mutants did not (Figure  5C). On the contrary, overexpression of the 
R144G/E300* showed significant reduction in cytokine production, suggesting that this mutant may 
impair function of endogenous CRACR2A. Overall, our cytokine analysis suggested that expression of 
mutants derived from each of the CRACR2A alleles could not rescue cytokine production in CRACR2A 
KO T cells.
Mutations of E278D and R144G/E300* lead to reduced Ca2+ influx and 
JNK activation
We next checked whether individual mutants could rescue TCR- proximal events in CRACR2A KO T 
cells. Earlier we showed that loss of CRACR2A impaired TCR stimulation- induced SOCE and JNK 
phosphorylation in T cells (Srikanth et al., 2016). Accordingly, CRACR2A KO Jurkat T cells showed 
reduced Ca2+ entry triggered by TCR stimulation (Figure  6A). Expression of WT CRACR2A fully 
rescued the decreased level of Ca2+ entry in KO cells while that of R144G/E300* and E278D mutants 
did not. We observed similar results when SOCE was triggered by passive depletion of intracellular 
Ca2+ stores using thapsigargin (Figure 6B). Interestingly, these two mutants behaved differently in 
activation of the JNK signaling pathway. While WT and the E278D mutant rescued phosphorylation of 
JNK, R144G/E300* mutant failed to do so (Figure 6C). These results indicate that while R144G/E300* 
mutant has a defect in both Ca2+ entry and JNK activation due to truncation of the coiled coil, proline- 
rich and Rab GTPase domains, E278D mutant has a selective defect in Ca2+ signaling.
CRACR2AR144G/E300* has defect in the interaction with downstream 
regulators and shows abnormal cytoplasmic distribution
The C- terminal Rab GTPase domain of CRACR2a contains the conserved residues required for GTP 
binding and hydrolysis as well as a prenylation site for membrane anchoring (Figure 2C). The N- ter-
minal EF- hand motif and coiled- coil domains are involved in sensing intracellular Ca2+ levels and 
stabilizing ORAI1- STIM1 interaction (Srikanth et  al., 2010a). Also, the longer isoform, CRACR2A, 
which localizes to intracellular vesicles, translocates to the immunological synapse, and interacts with 
a signaling adaptor molecule, Vav1, through its proline- rich domain (PRD) (Srikanth et al., 2016).
To gain insight into the mechanism underlying the defective function of the mutants, we checked 
the interaction of these mutants with three known interacting partners, ORAI1, STIM1, and Vav1 using 
co- immunoprecipitation. These results showed that the R144G/E300* mutant failed to interact with 
all the molecules, whereas the E278D mutant retained binding to all three partners, similar to WT 
CRACR2A (Figure 7A and B). Confocal analysis showed that WT CRACR2A and E278D mutant local-
ized in the proximal Golgi area and translocated to the interface of anti- CD3 antibody- coated cover-
slips after stimulation (Figure 7C). However, the R144G/E300* mutant showed a diffuse cytoplasmic 
localization and was not enriched at the interface in stimulated cells. These results suggest that while 
E278 behaves similar to WT CRACR2A in interacting with binding partners (under our experimental 
conditions) as well as intracellular localization under resting and stimulated conditions, the R144G/
E300* mutant is impaired in all these functions. Deletion of protein interaction domains including 
the PRD and the C- terminal prenylation site is likely the cause loss of binding to its partners and 
cytoplasmic localization of the DM. Even though E278D retained binding to ORAI1/STIM1, it could 
not reconstitute SOCE or cytokine production in CRACR2A KO Jurkat T cells, suggesting that subtle 
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changes in the protein conformation due to this mutation may alter its affinity for interaction with 
ORAI1/STIM1 under physiological conditions, which is not recapitulated in our biochemical studies 
performed using overexpression.
Discussion
Our study describes a novel cause of primary immunodeficiency in humans due to compound hetero-
zygous mutations in CRACR2A. The resulting clinical phenotype is more in keeping with antibody 
Figure 6. SOCE and JNK phosphorylation in T cells expressing individual allelic mutations in CRACR2A. (A) Representative traces showing averaged 
SOCE from control (48 cells) or CRACR2A- KO Jurkat T cells (KO) transduced with an empty vector (55 cells) or those encoding FLAG- tagged WT 
CRACR2A (45 cells), CRACR2AE278D (E278D, 40 cells), or CRACR2AR144G/E300* (DM, 50 cells) mutants (left). Cells were stimulated with anti- CD3 antibodies, 
followed by ionomycin treatment in the presence of external solution containing 2 mM Ca2+. Bar graphs show averaged baseline subtracted peak SOCE 
(± s.e.m.) from anti- CD3 antibody and ionomycin treatments, from three independent experiments (right). (B) Representative traces showing averaged 
SOCE induced by thapsigargin (TG) treatment from control (52 cells) or CRACR2A- KO Jurkat T cells (KO) transduced with empty vector (46 cells) or 
those encoding FLAG- tagged WT CRACR2A (49 cells), CRACR2AE278D (E278D, 51 cells), or CRACR2AR144G/E300* (DM, 50 cells) mutants (top). Cells were 
stimulated with thapsigargin in Ca2+- free solution to deplete the intracellular stores and exposed to external solution containing 2.0 mM Ca2+. Bar 
graphs below show averaged baseline subtracted SOCE levels (± s.e.m.) at the peak (center) or later time point (sustained – 900 s, bottom) from three 
independent experiments. (C) Phosphorylated JNK levels in control or CRACR2A KO Jurkat T cells stably expressing WT and indicated mutants of 
CRACR2A, stimulated with anti- CD3 antibody for indicated times. Graphs show average± SDM from three independent experiments. * p < 0.05, ** p < 
0.005, *** p < 0.0001.
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deficiency, although detailed immunological investigations show a combined immune defect with 
evidence of progressive lymphopenia and impaired T cell activation. At presentation, the patient 
was found to have profound panhypogammaglobulinaemia, however, subsequent investigations 
suggested that the intrinsic B cell function seems to be relatively preserved in this condition, and that 
failure of antibody production is most likely a consequence of inadequate T cell help. The same mech-
anism is likely to cause a reduction in the proportion of class switched memory B cells. Consequently, 
our investigations have focused on the function of T cells, and in particular CD4+ cells due to the 
Figure 7. Biochemical interactions and localization profiles of individual allelic mutations in CRACR2A. (A) Immunoprecipitation for detection of binding 
between WT and indicated mutants of CRACR2A (E278D, or DM) with ORAI1/STIM1. Lysates of HEK293T cells expressing FLAG- tagged CRACR2A in 
the presence of 6 X His- tagged ORAI1 and STIM1, were subjected to immunoprecipitation with anti- FLAG antibodies and analyzed by immunoblotting 
for detection of the indicated proteins. Bar graphs below show densitometry analysis of binding of CRACR2A to ORAI1 (left) and STIM1 (right), 
normalized to that of WT CRACR2A, from three independent experiments. (B) Immunoprecipitation for detection of binding between CRACR2A and 
VAV1. Lysates of HEK293T cells expressing FLAG- tagged WT or indicated mutants of CRACR2A in the presence of GFP- tagged VAV1, were subjected 
to immunoprecipitation with anti- FLAG antibodies and analyzed by immunoblotting for detection of indicated proteins. Bar graph below shows 
densitometry analysis of binding of CRACR2A to VAV1, normalized to that of WT CRACR2A, from three independent experiments. (C) Representative 
confocal images of CRACR2A KO Jurkat cells stably expressing N- terminally FLAG- tagged WT or indicated mutants of CRACR2A under resting 
conditions (top panels) or 20 min after dropping on stimulatory anti- CD3 antibody- coated coverslips (middle and bottom panels). The top panels 
showed images from the center of the cell. The middle panels show images from the bottom of the cell, which was in contact with the coverslip and the 
bottom panels showed images from the center of the anti- CD3 antibody- stimulated cell. F- Actin staining – green, anti- FLAG antibody staining – red. 
Images are representative of at least 10 cells in each condition. * p < 0.05, ** p < 0.005.
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known role of CRACR2A in their activation and also progressive selective CD4+ lymphopenia which 
was evident from the patient’s phenotype.
Previously we have characterized developmental and immunological phenotypes in mice with T 
cell- specific deletion of Cracr2a. Using 8–12 week- old animals housed in a specific pathogen free 
facility with limited exposure to environmental insults, we observed normal development and homeo-
stasis of CD4+ cells in Cracr2afl/fl Cd4- Cre mice (Woo et al., 2018). Similar to patient cells, CRACR2A 
KO murine T cells showed defect in SOCE as well as JNK- phosphorylation, thereby, reduction in cyto-
kine production, suggesting conserved function of CRACR2A in mouse and human T cells. Further, 
within the time frame of 8–12 weeks, no lymphopenia was observed in Cracr2afl/fl Cd4- Cre mice, unlike 
the patient in this study, who shows progressive loss of CD4+ T cells. Further studies examining T cell 
homeostasis in aged mice can uncover whether this phenotype is conserved in mice. It should be 
noted that the mice had T cell- specific deletion of Cracr2a, unlike the patient, that expresses, albeit 
at lower amounts, a mutant CRACR2A protein globally. Hence, patient T cells may also have indirect 
impact on survival, due to loss of CRACR2A in other cells/tissues.
To check the extent of function lost due to individual allelic mutants of CRACR2A, we reconsti-
tuted CRACR2A KO T cells with individual mutants. The more severe, truncated R144G/E300* mutant 
showed a profound impairment in both SOCE as well as JNK phosphorylation, and showed pheno-
types similar to CRACR2A KO T cells. Biochemical analysis showed that the R144G/E300* mutant 
lost binding to all known interacting partners, including ORAI1, STIM1, and Vav1 and had localiza-
tion pattern different from that of WT CRACR2A, which may contribute to its defect in function. 
The drastic defect of R144G/E300* mutant was expected because it does not have the C- terminal 
proline- rich and Rab GTPase domains, which are necessary for protein interaction and subcellular 
localization of CRACR2A proteins. Consequently, cells expressing the R144G/E300* mutant did not 
show any rescue of SOCE, JNK phosphorylation or cytokine production. The E178D point mutation 
on the other hand, could reconstitute the defect in JNK phosphorylation observed in CRACR2A KO 
T cells, retained binding to ORAI1, STIM1 and Vav1, and showed localization pattern similar to WT 
CRACR2A. However, in spite of being able to interact with ORAI1 and STIM1 under overexpres-
sion conditions, the E278D mutant could not rescue the SOCE defect observed in CRACR2A KO T 
cells. These data suggest that under physiological conditions with limiting amounts of ORAI1 and 
STIM1, E278D mutant may have impairment in binding to these proteins, which is not recapitulated in 
our biochemical experiments using overexpression. Consequently, the E278D mutant also could not 
rescue the defect in cytokine production observed in CRACR2A KO T cells.
Examination of patient PBMCs showed reduced expression of total CRACR2A protein, corre-
sponding to the long isoform, suggesting that transcription/translation from both alleles contribute 
to total levels of endogenous CRACR2A protein. Further, in spite of multiple attempts, we could 
not detect any band corresponding to the R144G/E300* mutant, with an expected MW of ~35 KDa, 
suggesting that the mutant protein may be unstable and degraded. In support of this hypothesis, 
exogenous expression analysis suggested that while the E178D mutant was expressed at levels similar 
to WT, the R144G/E300* double mutant consistently showed lower expression (Figure  1—figure 
supplement 1). Furthermore, CRACR2A transcript levels were also significantly reduced at basal level 
and upon stimulation in patient T cells compared to healthy control. These data suggest that impair-
ment observed in patient T cells can be derived from multiple factors including functional defects and 
mRNA/protein stabilities.
In this study, we performed extensive characterization of CRACR2A variants and consequently 
demonstrated significant functional impairment of the patient’s T cells. However, the resulting clinical 
phenotype is possibly less severe than might be expected. This is not necessarily surprising, since 
discordance between apparent functional immune abnormalities and clinical outcome has also been 
seen with other inborn errors of immunity caused by mutations in STIM1 (Rice et  al., 2019). Our 
study also focused on the effects of CRACR2A deficiency primarily on T cell function. However, our 
results do not exclude the possibility that CRACR2A can play a role in activation of other innate and 
adaptive immune cell types, which may have indirect contribution to lymphopenia observed in the 
patient. Further detailed analysis of other cell types in combination with Cracr2a KO mouse models 
will provide insight into the role of CRACR2A in the immune response. In conclusion, our results 
suggest that human CRACR2A insufficiency underlies progressive loss of immune competence by 
uncoupling TCR activation from Ca2+ and MAPK signaling. Given the resultant clinical phenotype and 
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range of associated immunological abnormalities, we propose that CRACR2A deficiency should be 
included within the group of combined immunodeficiency disorders in the IEI classification.
Materials and methods
 Continued on next page
Key resources table 
Reagent type (species) or  
resource Designation Source or reference Identifiers Additional information
Gene  
(Homo sapiens) CRACR2A NCBI Gene ID: 84,766
Strain, strain background 
(Escherichia coli) DH5α Thermo fisher Scientific Cat# 18265017
Cell line (Homo sapiens) Jurkat E6- 1 T cells ATCC
Not tested for 
mycoplasma Cat# TIB- 152
Cell line (Homo sapiens) HEK293T ATCC
Not tested for 
mycoplasma Cat# CRL- 3216
Cell line (Mus musculus) CD40L- expressing L cell fibroblasts Diehl et al., 2008
Irradiated at 50 Gy  
for 50 minutes prior  
to use
Cell line (Mus musculus) M2- 10B4 bone marrow stromal cells Lemoine et al., 1988
Irradiated at 57 Gy  
for 57 minutes prior  
to use
Transfected construct (Homo 
sapiens) Primers for plasmid construction This paper Supplementary file 1
Biological sample (Homo- sapiens)
Primary human peripheral blood 
mononuclear cells This paper
Isolated from the  
patient and healthy  
controls
Antibody
Anti- human  
Phospho JNK  
(mouse monoclonal) Cell Signaling Technologies Cat# 9,255 Flow cytometry (1:100)
Antibody Anti- Human STIM1(rabbit) Cell Signaling Technologies Cat# 5,668 S WB (1:5000)
Antibody
Anti- His- tag




monoclonal) Millipore Sigma Cat# F3040 WB (1:5000)
Antibody
Anti- human  
ORAI1
(rabbit  
polyclonal) Millipore Sigma Cat# AB9868 WB (1:5000)
Antibody
Anti- Vav1




monoclonal) Santa Cruz Biotechnology Cat# sc- 47778 WB (1:2500)
Antibody
anti- human CD3 antibody (mouse 
monoclonal) Bio X Cell Clone OKT- 3 1 μg/ml
Antibody
Anti- human CD28 antibody (mouse 











gama- PE- Cy7 eBioscience Clone 45.B3
FACS
5 μl/test
Antibody Ant- IL2- PE eBioscience Cat# MQ1- 17H12
FACS
5 μl/test
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Reagent type (species) or  











Anti- human,  




































































Anti- human,  




































F(ab′)two goat  
anti- human IgM/IgG/IgA
Jackson Immuno
Research Cat. #: 109- 006- 129 10 μg/ml
Antibody
Anti- human  
CD138- APC
(mouse  




DNA reagent FGllF This paper N/A
 Continued on next page
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Reagent type (species) or  
resource Designation Source or reference Identifiers Additional information
Recombinant  












































CRACR2A WT This paper
Details in  
Supplementary file 1
Recombinant  
DNA reagent FG11F CRACR2AE278D This paper
Details in  
Supplementary file 1
Recombinant  
DNA reagent FG11F CRACR2AR144G This paper










SureSelect XT Human  








































protein IL- 2 Roche Cat. #: HIL2- RO
Peptide,  
recombinant  
protein IL- 21 Peprotech Cat. #: 200–21 50 ng/ml
Peptide,  
recombinant  
protein IL- 2 Peprotech Cat# 200–02 20 units/ml
Commercial  
assay or kit aCD3 plates Corning Cat. #:354,725 10 ng/ml
Commercial  
assay or kit B cell isolation kit Miltenyi Biotech, Cat. #:130- 091- 151 100 U/ml
 Continued
 Continued on next page
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Reagent type (species) or  




DNA Blood kit Qiagen Cat. #:61,104
Commercial  
assay or kit Human IgG ELISA Quantitation Set Bethyl Laboratories Inc, Cat. #: E80- 104
Commercial  
assay or kit Human IgM ELISA Quantitation Set Bethyl Laboratories Inc, Cat. #: E80- 100
Commercial  
assay or kit
MagniSort human naïve CD4+ T cell 




Transcription Factor staining Buffer set Thermofisher Scientific Cat. #: 2229155
Chemical  
compound,  





drug 3HThymidine Perkin Elmer Cat. #: 027001
Chemical  
compound,  










drug Fura 2- AM Thermofisher Scientific Cat# F1221
Chemical  
compound,  
drug Brefeldin A Thermofisher Scientific Cat# 00- 4506- 51
Chemical  
compound,  






acetate (PMA) EMD Millipore Cat# 5.00582.0001
Chemical  
compound,  
drug Ionomycin EMD Millipore Cat# 407,951
Chemical  
compound,  
drug Polybrene Millipore Sigma Cat# TR- 1003
Chemical  
compound,  
drug Puromycin Invivogen Cat# ant- pr- 1
Chemical  
compound,  
drug Blasticidin Invivogen Cat# ant- bl- 05
Chemical  
compound,  




Fixable Viability  
Dye eFluor 780 eBioscience Cat# 65- 0865- 14 1 μl/ml of cells
Software,  
algorithm FlowJo v10 TreeStar
 Continued
 Continued on next page
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Reagent type (species) or  










algorithm Image J NIH
Software,  
algorithm Fluoview FV10i Confocal Microscope Olympus
Software,  
algorithm Fluoview software FlowJo, LLC
Software,  
algorithm Exome sequence analysis (various) Please see methods section
Other LAS- 3000 LCD camera FujiFilm
Other ECM 830 electroporator BTX
Other BD Fortessa flow cytometer BD Biosciences
Other Cytoflex LX flow cytometer Beckman Coulter
Other HiSeq 3,000 Illumina
 Continued
Ethical approval for this study was obtained from Leeds East Yorkshire Research ethics Committee 
(18/YH/0070). Written consent to conduct and publish this study was obtained from all participants.
Exome sequence preparation
Genomic DNA was purified from whole blood using QIAamp DNA Blood kit (Qiagen) with quality and 
concentration assayed using a TapeStation (Agilent). Exome sequence data was produced by batch 
sequencing with other non- related samples. Samples were sonicated using a Covaris E220 Focused- 
ultrasonicator to fragment the DNA to a median size of approximately 250–300 bp. Libraries were 
generated using Agilent SureSelect XT Human All Exon V5, using a standard protocol, receiving a 
unique index sequence and were then pooled to form equimolar pools. These were sequenced on 
a 150 bp paired end Illumina HiSeq 3,000 (Illumina, San Diego, CA, United States) with an average 
depth of coverage of x30.
Candidate variant selection
Exome sequences were trimmed and checked for quality control using CutAdapt (Andrews, 2010) 
and FastQC (Andrews, 2010) via Trim- galore (Krueger, 2015). Reads were aligned to GrCh37 using 
BWA- MEM (Li and Durbin, 2009). GATKv3 best practices were applied for genomic analysis. Reads 
were sorted and marked with Picard SortSam and MarkDuplicates (Broad Institute), respectively. 
The read alignments were readjusted for optimal local alignment using IndelRealigner (GATK), Base 
Quality Score Recalibration (GATK) was used to estimate base call accuracy by detecting systematic 
sequencing errors, followed by (GATK) PrintReads. HaplotypeCaller was used to produce gVCFs via 
local re- assembly of haplotypes. GenotypeGVCFs (GATK) was used for joint genotyping with other 
non- related samples and in- house controls for an analysis group size of 34 (Auwera et al., 2018). 
Variant Quality Score Recalibration (GATK) was used to filter out probable artifacts from the callset. A 
total of 719,868 variants were present for the combined cohort, with 49,891 of these variants occur-
ring in the proband sample.
Filtering and prediction of functional consequences was performed by annotating data using 
Variant Effect Predictor (VEP) (McLaren et al., 2016), Exome Variant Server (EVS), The Single Nucle-
otide Polymorphism database (dbSNP), ClinVar, and the Exome Aggregation Consortium and the 
Genome Aggregation Database (gnomAD) (Lek et  al., 2016). Filtering of common variations and 
annotation terms was performed using the tool VCFhacks (Parry, 2015). Candidate variants were 
required to pass the following filtering conditions: read frequency (count/coverage) between 20 
and 100%, according to VEP- annotation at least one canonical transcript is affected with one of the 
following consequence: variants of the coding sequence, frameshift, missense, protein altering, splice 
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acceptor, splice donor, or splice region; an in- frame insertion or deletion; a start lost, stop gained, or 
stop retained, or according to VEP a gnomAD frequency of unknown, less of equal to 0.01, or with 
clinical significance ‘path’.Cohort- specific filtering retained functional variants that were present in at 
least one case but absent for in- house filtering controls or having indication of misalignment or index 
swapping. The resulting candidate list of variants consisted of rare variants that were of unknown or 
potentially damaging significance.
Candidate variants were also annotated with terms from Gene Ontology, GeneRIF, Biogrid inter-
action, OMIM, NCBI summary, MGI phenotype, MorbidMap, VOC MammalianPhenotype, UniProtKB, 
PDB, and HMD human phenotype (Parry, 2015). Variants were flagged if they had any annotation 
related to the disease phenotype, were predicted pathogenic, or were in a gene known to cause 
immunological responses. A filter for all known PID genes was also used to flag any candidates that 
may have been otherwise excluded. A total of 48 recessive candidate variants (compound heterozy-
gous of homozygous) were identified in 34 genes. Filtering based on gene annotation removed genes 
with no known immunological significance.
The top gene candidate, calcium release activated channel regulator 2  A (CRACR2A) 
ENSG00000130038 (also annotated by previous gene symbol EFCAB4B), contained three variants; 
ENST00000440314 (1) missense c.430A > G, p.R144G, exon 6/20, novel, 12:3788175, Ref T, Alt C, (2) 
missense c.834G > T, p.E278D, exon 9/20, gnomAD 0.0001647 rs541326469, 12:3765501 Ref C, Alt 
A, and (3) stop- gained c.898G > T p.E300*, exon 10/20, novel, 12:3763526 Ref C, Alt A. LDpop Tool 
via LDlink (with appropriate population EAS) was used to guide interpretation prior to confirmation by 
genomic DNA sequencing of relatives. Chr12:3763526 (p.E300*) and chr12:3788175 (p.R144G) were 
not in dbSNP build 151, indicating potential LD, inherited together from one parent and in trans with 
12:3765501 (p.E278D). The inheritance pattern (p.[R144G;E300*];[E278D]) was confirmed by Sanger 
sequencing of genomic DNA in the proband, mother, maternal grandmother, and the father. Ampli-
fication of genomic DNA for Sanger sequencing was performed by the standard PCR method. PCR 
clean- up was performed with ExoSAP- IT (Affymetrix). Sanger sequencing was then done using the 
same primers; Exon 6, (F-  ATGATTCCTGGCAGGTGAGA, R- ATTCCAGTGCAGGGACCAG), Exon 9 
(F-  GGCCCTGATGTTGAGTAGGT, R-  GTGAATGGCAGGGAAAGTGG), and Exon 10 (F- AAACAAG-
GTGAGGCCAGGG, R-  AGCC CAAA TCCT CTTT TCACAG). Sanger sequencing using BigDye Termi-
nator Cycle Sequencing Kit, version 3.1 (Applied Biosystems) and analysis on an ABI 3130XL DNA 
analyzer (Applied Biosystems).
Two candidate variants were also identified in UNC13D, a gene reported as causal for the reces-
sive PID Familial hemophagocytic lymphohistiocytosis syndromes (as reported in Genomics England 
panelapp). However, one variant was present at ~1% in the patient genetic ancestry population and 
not considered as potentially damaging. Variant 1: ENST00000207549.4 p.Arg411Gln, Polyphen - 
benign, SIFT – tolerated. East Asian allele frequency 0.008. gnomAD link 1; variant 2: East Asian allele 
frequency 0. gnomAD link 2 ENST00000207549.4 HGVSpc.753 + 1 G> T, pLoF - high- confidence, 
East Asian allele frequency 0, gnomAD link 2. No other candidate biallelic variants were considered 
causal bases on annotation or variant effect. No dominant gain- of- function variants were considered 
as causal candidates.
Chemicals and antibodies
Fura 2- AM was purchased from Invitrogen (Carlsbad, CA). Thapsigargin, PMA (Phorbol 12- myristate 
13- acetate), and ionomycin were purchased from EMD Millipore. Brefeldin A was purchased from 
eBioscience. Antibody for detection of CRACR2A (15206–1- AP) was purchased from Proteintech. 
Antibodies for detection of Vav1 (2502), STIM1 (5668) and His tag (12,698 S) were purchased from 
Cell Signaling Technologies. Antibodies for detection of FLAG tag (F3040) and ORAI1 (AB9868) were 
purchased from Millipore Sigma. Antibody for detection of β-actin (sc- 47778) was obtained from 
Santa Cruz Biotechnology.
Plasmids and cells
Full- length cDNA of human CRACR2A- a (NCBI Reference Sequence: NM_001144958.1) was cloned 
into a lentiviral vector, FGllF (kind gift from Dr. Dong Sun An, UCLA) with a N- terminal FLAG tag as 
previously described (Srikanth et al., 2010a; Srikanth et al., 2016). Various mutants of CRACR2A- a 
were generated by PCR amplification and site- directed mutagenesis using primers described in 
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Supplementary file 1. All the clones were verified by sequencing. Myc- ORAI1 and Myc- STIM1 plas-
mids had been described previously (Gwack et al., 2007; Srikanth et al., 2019). Vav1- GFP clone was 
purchased from Addgene. HEK293 and Jurkat E6- 1 T cell lines were obtained from American Type 
Culture Collection Center (ATCC, Manassas, VA).
Human B cell culture, staining, and analysis
PBMCs were isolated from peripheral blood by density dependent centrifugation with Lymphoprep 
(Axis Shield, Norway). Total B cells were isolated by negative selection with a memory B cell isolation 
kit according manufacturer’s instructions (Miltenyi Biotech, USA). B cells were cultured as previously 
described (Cocco et al., 2012) using gamma- irradiated CD40L- L cells and 2 µg/ml F(ab′)two goat 
anti- human IgM/IgG/IgA (Jackson ImmunoResearch) supplemented with 20  U/ml IL- 2 (Roche) and 
50 ng/ml IL- 21 (Peprotech) as the initial T- depedent stimulus. Cells were monitored for changes in cell 
surface antigen expression using anti- CD38- APC- Cy7 (HB- 7; BD Biosciences), anti- CD138- APC (44F9; 
Miltenyi Biotec), as well as 7- AAD- PerCP- Cy5 (BD Biosciences) to identify live cells. Flow cytometry 
was performed using a or a CytoFLEX S or LX (Beckman Coulter). Analysis was performed using 
FlowJo v10 (TreeStar). Supernatants were collected at day 6 and day 13 from the differentiation assays 
and assessed for Ig levels using human IgM ELISA Quantitation Set (E80- 100) or Human IgG ELISA 
Quantitation Set (E80- 104) (Bethyl Laboratories Inc, USA) according to manufacturer’s instructions on 
a Berthold 96- well plate reader. ELISA absorbance values were analyzed at 450 nm and Ig concentra-
tions calculated from standard curves.
Generation of CRACR2A-KO Jurkat T cells using CRISPR-Cas9 system
To generate lentiviruses for transduction, HEK293T cells were transfected with plasmid(s) encoding 
sgRNA and packaging vectors (pMD2.G and psPAX2 – from Addgene) using calcium phosphate trans-
fection method. Cas9 encoding lentivirus was generated using the same technique. Culture superna-
tants were harvested at 48 and 72 hr post transfection and used for infection (50% of cas9- encoding 
virus +50% of sgRNA- encoding virus) of Jurkat T cells together with polybrene (8 µg/ml) using the 
spin- infection method. Cells were selected with puromycin (1 µg/ml) and blasticidin (5 µg/ml) 48 hrs 
post infection. The sgRNA sequences are described in Supplementary file 1.
Single-cell Ca2+ imaging and confocal microscopy
Jurkat or human PBMCs were loaded at 1 × 106 cells/ml with 1 μM Fura 2- AM for 30 min at 25 °C and 
attached to poly- D- lysine- coated coverslips. Intracellular [Ca2+] measurements were performed using 
essentially the same methods as previously described (Srikanth et al., 2010b). Confocal laser scan-
ning microscopy was performed using Fluoview FV10i Confocal Microscope (Olympus), images were 
captured with a 60 x oil objective. Images were processed for enhancement of brightness or contrast 
using Fluoview software.
Immunoprecipitation and immunoblotting
For immunoprecipitation, 6 x His- tagged ORAI1 and 6xHis- tagged STIM1 or Vav1- GFP together with 
empty vector or FLAG- tagged WT CRACR2A- a, FLAG- tagged CRACR2AE278D or CRACR2AR144G, E300* 
was transfected into HEK293T cells. Transfected cells (2 × 107) were lysed in lysis buffer (20 mM Tris- Cl, 
2 mM EDTA, 135 mM NaCl, 10% (vol/vol) glycerol, 0.5% Igepal CA- 630, protease inhibitor mixture, 
pH 7.5) and centrifuged at 100,000 x g for 1 hr before preclearing with protein G- Sepharose. Lysates 
were immunoprecipitated with anti- FLAG antibody- conjugated resin for 6  hr. Immunoprecipitates 
were washed five times in lysis buffer and analyzed by immunoblotting. For detection of CRACR2A- a, 
5 × 106 HEK293 or CRACR2A- deficient Jurkat T cells stably expressing empty vector, FLAG- tagged 
WT CRACR2A- a, CRACR2AE278D, or CRACR2AR144G, E300* were lysed in in RIPA buffer (10 mM Tris- Cl pH 
8.0, 1% Triton X- 100, 0.1% SDS, 140 mM NaCl, 1 mM EDTA, 0.1% sodium deoxycholate and protease 
inhibitor cocktail [Roche]) and centrifuged to remove debris. For immunoblot analyses, lysates were 
separated on 10% SDS- PAGE and proteins were transferred to nitrocellulose membranes and subse-
quently analyzed by immunoblotting with relevant antibodies. Chemiluminescence images were 
acquired using an Image reader LAS- 3000 LCD camera (FujiFilm).
Human T cell culture, staining, and analysis
Peripheral blood mononuclear cells (PBMCs) were obtained under federal and state regulations 
from the CFAR Virology core Laboratory at UCLA that were prepared from buffy coats from healthy, 
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unidentified adult donors using Ficoll- PAQUE gradients. PBMCs from healthy control and patient 
were activated for 48 hr on a plate coated with 10 µg/ml of anti- CD3 antibody (OKT3, Bio X Cell) 
and cultured in T cell media (DMEM containing 20% fetal bovine serum and 1% Pen- Strep) supple-
mented with 5 µg/ml of anti- CD28 antibody (Bio X cell), and 20 U/ml IL- 2 (Peprotech) for ThN differ-
entiation. The cells were expanded for a further 4 days with IL- 2 and on day 6, cells were extensively 
washed and activated with 20 nM of PMA, 1 µM of ionomycin, and Brefeldin A (3 µg/ml) for 5 hr, 
surface stained with anti- CD4- FITC, and intracellularly stained with anti- IFN-γ-PE. CD4- FITC- positive 
cells were gated for analysis. For reconstitution of CRACR2A- a in CRACR2A- a- deficient PBMCs, naive 
CD4+ T cells were enriched by magnetic sorting from single- cell suspensions using MagniSort naive 
CD4+ T cell enrichment kit (catalog # 8804- 6814- 74) according to manufacturer’s instructions (Ther-
moFisher Scientific). Cells were activated and cultured as described above. Cells were infected with 
lentiviruses encoding cas9 together with those encoding sgRNAs targeting CRACR2A- a on day 1 and 
with lentiviruses encoding WT CRACR2A- a, CRACR2AE278Dor CRACR2AR144G, E300* together with empty 
vector on day 2. 48 hr after infection, cells were selected with 1 µg/ml of puromycin and 5 µg/ml blas-
ticidin for 16 hr and then expanded for further 2 days with fresh media. On day 7, cells were stimulated 
with 10 µg/ml of anti- CD3 antibody, 5 µg/ml of anti- CD28 antibody and Brefeldin A (3 µg/ml) for 5 hr, 
intracellularly stained with anti- IFN-γ-PE (4 S.B3). For cytokine staining, 1 × 106 Jurkat T cells were 
fixed with 4% p- formaldehyde for 15 mins, permeabilized with 0.5% saponin, blocked and stained 
with anti- IL- 2- PE antibody from Thermofisher Scientific. For flow cytometry, the following human 
specific antibodies were used: CD4- FITC (OKT4, eBioscience), IFN-γ-PE- Cy7 (45.B3, eBioscience) and 
IL- 2- PE (MQ1- 17H12, eBioscience). Data were acquired using FACSCalibur (Becton Dickinson) or BD 
LSRFortessa cell analyzers and analyzed using FlowJo software (Tree Star). ELISA was performed on 
human PBMCs harvested from healthy control and patient for detection of IL- 2 (ThermoFisher, #88- 
7025- 88) and TNF (ThermoFisher, # 88- 7324- 88).
T-(Helper) cell phenotyping
Whole EDTA blood was stained with a combination of CD3- V500, CD4- BV421, CCR6- Pe and CXCR3- 
Alexa- Fluoro 647 (all antibodies from Becton Dickinson, UK) at room temperature protected from 
light. Erythrocytes were subsequently lysed using BD red cell lysis solution and following a further 
10 min incubation the samples were washed by centrifugation (1500 rmp for 6 min) using PBS/1% 
FBS. Following the final wash, cells were resuspended in 400 µl of PBS + 0.5% formaldehye and cells 
analysed using a FACSCanto II flow cytometer (BD) using FACSDIVA software. The gating strategy is 
show in Figure 1—figure supplement 1B.
RNA isolation, cDNA synthesis, and real-time quantitative PCR
Total RNA from cells harvested in TRIzol Reagent (Thermofisher Scientific) was isolated using the 
Direct- zol RNA isolation kit (Zymo Research). RNA quantity and quality were confirmed with a Nano-
Drop ND- 1000 spectrophotometer. cDNA was synthesized using 1–2 µg of total RNA using oligo(dT) 
primers and Maxima Reverse Transcriptase (Thermofisher Scientific). Real- time PCR was performed 
using iTaq Universal SYBR Green Supermix (Bio- Rad) and an iCycler IQ5 system (Bio- Rad) using gene- 
specific primers described in Supplementary file 1. Threshold cycles (CT) for all the candidate genes 
were normalized to those of 36B4 to obtain ΔCT. The specificity of primers was examined by melt- 
curve analysis and agarose gel electrophoresis of PCR products.
Measurement of JNK phosphorylation by intracellular staining
CRACR2A- deficient Jurkat T cells stably expressing empty vector, FLAG- tagged CRACR2A- a, 
CRACR2AE278D, or CRACR2AR144G, E300* were left untreated or stimulated with 10 µg/ml anti- CD3 anti-
body (OKT3) for indicated times. Human PBMCs isolated from healthy control and patient were stim-
ulated as described above. Cells were fixed with 4% PFA, permeabilized with ice- cold methanol and 
stained with phospho- SAPK/Jnk mAb (Cell Signaling, #9257). Cells were washed twice with PBS and 
analyzed with a FACSCalibur flow cytometer (Becton Dickinson) and FlowJo software.
Statistical analysis
Statistical analysis was performed using the Origin2018b software (OriginLab, Northampton, MA, 
USA). Data are presented as mean  ±  s.e.m. Statistical significance to compare two quantitative 
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groups was evaluated using two- tailed/unpaired t- test. A critical value for significance of p  <  0.05 
was used throughout the study, and statistical thresholds of 0.05, 0.005 as well as 0.0005 are indicated 
on the figures by stars (see legends for detail).
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